- Home
- BLTE vs CRTO Comparison
BLTE vs CRTO Comparison
Compare BLTE & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- CRTO
- Stock Information
- Founded
- BLTE 2018
- CRTO 2005
- Country
- BLTE United States
- CRTO France
- Employees
- BLTE N/A
- CRTO N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- CRTO Advertising
- Sector
- BLTE Health Care
- CRTO Consumer Discretionary
- Exchange
- BLTE Nasdaq
- CRTO Nasdaq
- Market Cap
- BLTE 2.1B
- CRTO 2.1B
- IPO Year
- BLTE 2022
- CRTO 2013
- Fundamental
- Price
- BLTE $66.70
- CRTO $35.02
- Analyst Decision
- BLTE Strong Buy
- CRTO Buy
- Analyst Count
- BLTE 4
- CRTO 10
- Target Price
- BLTE $96.67
- CRTO $54.67
- AVG Volume (30 Days)
- BLTE 53.3K
- CRTO 331.9K
- Earning Date
- BLTE 03-17-2025
- CRTO 05-01-2025
- Dividend Yield
- BLTE N/A
- CRTO N/A
- EPS Growth
- BLTE N/A
- CRTO 115.91
- EPS
- BLTE N/A
- CRTO 1.90
- Revenue
- BLTE N/A
- CRTO $1,933,289,000.00
- Revenue This Year
- BLTE N/A
- CRTO N/A
- Revenue Next Year
- BLTE N/A
- CRTO $7.82
- P/E Ratio
- BLTE N/A
- CRTO $19.28
- Revenue Growth
- BLTE N/A
- CRTO N/A
- 52 Week Low
- BLTE $31.01
- CRTO $33.15
- 52 Week High
- BLTE $86.53
- CRTO $49.93
- Technical
- Relative Strength Index (RSI)
- BLTE 58.99
- CRTO 38.19
- Support Level
- BLTE $64.10
- CRTO $34.53
- Resistance Level
- BLTE $67.40
- CRTO $38.48
- Average True Range (ATR)
- BLTE 2.33
- CRTO 1.42
- MACD
- BLTE -0.33
- CRTO 0.16
- Stochastic Oscillator
- BLTE 37.74
- CRTO 17.70
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.